Drug Use Evaluation of Iron with Folic Acid During Pregnancy at Alem Ketema Enat Hospital, North shoa, Amhara, Ethiopia

Authors

  • Gizew Dessie Asres B.pharm, MPH
  • Yibeltal Aniley Tadesse b.Pharm

DOI:

https://doi.org/10.37591/tdd.v4i3.58

Abstract

Drug use evaluation (DUE) is the ongoing, systematic and criteria-based program of medicine evaluations that will ensure appropriate medicines use. Correct dosage of iron with folic acid (IFA) is recommended by WHO to prevent iron deficiency anemia during pregnancy. Even if it affects populations, pregnant mothers are prone to develop anemia. Iron deficiency anemia contributes for 95% of anemia during pregnancy reflecting the need for iron to pregnant women. Foliatesupplementation is encouraged before conception, but still has significant protective effect for birth weight. In addition to the mother, anemia has a significant impact to the fetus. Anemia has contributed 20% of maternal deaths in Africa.The national guideline of Ethiopia recommends a minimum of 6 monthssupply of IFA during pregnancy.A cross-sectional criterias based study design was conducted on 348 antenatal care(ANC) attendants retrospectively from October to June 2016 to evaluate the extent of correct dosage of IFA at Alem Ketema Enat hospital. This data was analyzed using MS excel 2010 and the result shows only 19% of ANC attendants took the correct IFA dosage as recommended by WHO and the national protocol. Therefore, the hospital should design quality improvement project on the correct supplementation of IFA to pregnant women.

 

Keywords: Drug use evaluation, iron with folic acid, pregnancy, WHO drug use evaluation criteria, North Shoa, Ethiopia

 

Cite this Article

Gizew Dessie, Yibeltal Aniley. Drug Use Evaluation of Iron with Folic Acid During Pregnancyat Alem Ketema Enat Hospital, North Shoa, Amhara, Ethiopia. Trends in Drug Delivery. 2017; 4(3): 1–8p.

Downloads

Published

2018-03-16

Issue

Vol. 4 No. 3 (2017)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.